^
    Back
    Association details:
    Biomarker:NTRK3 fusion
    Cancer:Ampulla of Vater Carcinoma
    Drug:Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Published date:
    04/27/2023
    Excerpt:
    Ampullary Adenocarcinoma...Good PS….Targeted Systemic Therapies:...Useful in Certain Circumstances:...Entrectinib (if NTRK gene fusion positive).
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Solid Tumor)
    Title:

    entrectinib (Rozlytrek ®) is accepted for use within NHSScotland.

    Excerpt:
    entrectinib (Rozlytrek) is accepted for use within NHSScotland....as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion